[Efficacy of myelopid in immunodeficiency states].
Petrov
R V
RV
Borisova
A M
AM
Glazko
A V
AV
Simonova
A V
AV
Stepanenko
R N
RN
D028341:Activins; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000361:Agammaglobulinemia / Q000188:drug therapy*; D001402:B-Lymphocytes / Q000187:drug effects; D001991:Bronchitis / Q000276:immunology; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D007958:Leukocyte Count / Q000187:drug effects; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology; D009842:Oligopeptides; D010455:Peptides / Q000627:therapeutic use*; D011014:Pneumonia / Q000276:immunology; D012074:Remission Induction / Q000379:methods; D013601:T-Lymphocytes / Q000187:drug effects
D000276:Adjuvants, Immunologic; D009842:Oligopeptides; D010455:Peptides; C044147:activin B; D028341:Activins; C048617:myelopeptides
Effektivnost' deĭstviia mielopida pri immunodefitsitnykh sostoianiiakh.